

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120)

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Biotronik UK • Boston Scientific • Cameron Health • Medtronic UK • Sorin Group • St Jude Medical UK <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • Afiya Trust • Arrhythmia Alliance • Black Health Agency • British Cardiac Patients Association • Cardiac Risk in the Young • Cardiomyopathy Association • Counsel and Care • Equalities National Council • Grown Up Congenital Heart Patients Association • Heart Care Partnership (UK) • Heart UK • Muslim Council of Britain • Muslim Health Network • Network of Sikh Organisations • SADS UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p>	<p><u>General</u></p> <ul style="list-style-type: none"> • Association of British Healthcare Industries • Board of Community Health Councils in Wales • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • EUCOMED • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • National Pharmacy Association • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Actavis UK (amiodarone, bendroflumethiazide, diltiazem, felodipine, fosinopril, furosemide, lisinopril, nevigolol, perindopril, ramipril, trandolapril, verapamil) • Alliance Pharmaceuticals (Acenocoumarol, Chlortalidone) • Bayer (nifedipine, nimodipine)

National Institute for Health and Clinical Excellence

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120)

Issue date: December 2011

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association for Nursing in Cardiac Care • British Association for Services to the Elderly • British Association of Emergency Medicine • British Atherosclerosis Society • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Nuclear Cardiology Society • British Society for Heart Failure • College of Emergency Medicine • Heart Rhythm UK • National Heart Forum • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society of Cardiothoracic Surgery of Great Britain and Ireland • United Kingdom Clinical Pharmacy Association • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • South Tyneside PCT • Welsh Assembly Government • Wolverhampton City PCT 	<ul style="list-style-type: none"> • Kent Pharmaceuticals(amiodarone) • LEO Laboratories (bumetanide) • Novartis Pharmaceutical UK(isradipine) • Roche (carvedilol cilazapril) • Sandoz (bisoprolol) • Sanofi Aventis (amiodarone, diltiazem metolazone) • Sigma Pharmaceuticals (amiodarone) • Teva UK (amiodarone) • UCB Pharma UK (moexipril, nifedipine) • Winthrop Pharmaceuticals UK (amlodipine, cilazapril, ramipril, indapamide) • Wockhardt UK (amiodarone, furosemide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Antithrombotic Trialists Collaboration • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts and The London • Cardiovascular Diseases Specialist Library • Cochrane Heart Group • CORDA • European Council for Cardiovascular Research • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Southampton Health Technology Assessment Centre • National Institute for Health Research Health Technology Assessment Programme

National Institute for Health and Clinical Excellence

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120)

Issue date: December 2011

Consultees	Commentators (no right to submit or appeal)
	<u>Associated Guideline Groups</u> <ul style="list-style-type: none"> • National Clinical Guideline Centre <u>Associated Public Health Groups</u> <ul style="list-style-type: none"> • Tbc

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120)

Issue date: December 2011

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute)

National Institute for Health and Clinical Excellence

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120)

Issue date: December 2011